Hur Hoon, Yu Eun Ji, Ham In-Hye, Jin Hye-Jin, Lee Dakeun
Department of Surgery, Ajou University School of Medicine, Suwon, Republic of Korea.
Brain Korea 21 Plus Research Center for Biomedical Sciences, Ajou University, Suwon, Republic of Korea.
Oncotarget. 2017 Feb 14;8(7):10994-11003. doi: 10.18632/oncotarget.14202.
It has been reported that serum insulin-like growth factor-binding protein 2 (IGFBP2) levels are elevated in various types of cancers. However, the clinicopathologic and prognostic implications of circulating IGFBP2 have never been investigated in gastric cancer. We tested IGFBP2 levels in the sera of 118 gastric cancer patients and 34 healthy controls using enzyme-linked immunosorbent assay (ELISA). The mean serum IGFBP2 level was significantly elevated in the gastric cancer patients compared to controls (805.23 ± 590.56 ng/ml vs. 459.61 ± 277.01 ng/ml; P < 0.001). Serum IGFBP2 levels were significantly higher in larger (> 6 cm) tumors (956.8 ± 734.0 ng/ml vs. 548.6 ± 364.0 ng/ml; P = 0.007) and in higher (T3/4) T stages (854.8 ± 621.4 ng/ml vs. 546.5 ± 315.1 ng/ml; P = 0.037). Multivariate Cox analysis showed that higher serum IGFBP2 level (> 400.01 ng/ml) was an independent prognostic factor predicting worse overall survival in patients with gastric cancer (hazard ratio (HR): 3.749, P = 0.034). When we divided patients into four groups based on blood IGFBP2 levels, survival was stratified. The HRs for death in the 3rd and 4th quartiles of serum IGFBP2 levels in comparison to that in the 1st quartile were 2.527 (P = 0.043) and 3.092 (P = 0.012). In conclusion, circulating IGFBP2 has potential as a biomarker predicting prognosis for gastric cancer patients.
据报道，血清胰岛素样生长因子结合蛋白2（IGFBP2）水平在各种类型癌症中均升高。然而，循环IGFBP2在胃癌中的临床病理及预后意义从未被研究过。我们采用酶联免疫吸附测定（ELISA）检测了118例胃癌患者和34例健康对照者血清中的IGFBP2水平。与对照组相比，胃癌患者血清IGFBP2平均水平显著升高（805.23±590.56 ng/ml对459.61±277.01 ng/ml；P<0.001）。血清IGFBP2水平在较大（>6 cm）肿瘤（956.8±734.0 ng/ml对548.6±364.0 ng/ml；P = 0.007）及较高（T3/4）T分期（854.8±621.4 ng/ml对546.5±315.1 ng/ml；P = 0.037）中显著更高。多因素Cox分析显示，较高的血清IGFBP2水平（>400.01 ng/ml）是预测胃癌患者总生存期较差的独立预后因素（风险比（HR）：3.749，P = 0.034）。当我们根据血液IGFBP2水平将患者分为四组时，生存情况出现分层。血清IGFBP2水平第三和第四四分位数与第一四分位数相比的死亡HR分别为2.527（P = 0.043）和3.092（P = 0.012）。总之，循环IGFBP2有潜力作为预测胃癌患者预后的生物标志物。
